États-Unis - anglais - NLM (National Library of Medicine)

ranbaxy pharmaceuticals inc. - amoxicillin (unii: 804826j2hu) (amoxicillin - unii:804826j2hu), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - powder, for suspension - 200 mg in 5 ml - amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: lower respiratory tract infections - caused by β-lactamase-producing strains of h. influenzae and m. catarrhalis . otitis media - caused by β-lactamase-producing strains of h. influenzae and m. catarrhalis . sinusitis - caused by β-lactamase-producing strains of h. influenzae and m. catarrhalis . skin and skin structure infections - caused by β-lactamase-producing strains of s. aureus , e. coli , and klebsiella spp. urinary tract infections - caused by β-lactamase-producing strains of e. coli , klebsiella spp. and enterobacter spp. while amoxicillin and clavulanate potassium is indicated only for the conditions listed above, infections caused by ampicillin-susceptible organisms are also amenable to treatment with amoxicillin and clavulanate potassium due

États-Unis - anglais - NLM (National Library of Medicine)

wg critical care, llc - penicillin g potassium (unii: vl775zth4c) (penicillin g - unii:q42t66vg0c) - penicillin g 1000000 [iu] - therapy: penicillin g potassium for injection, usp is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin g. therapy with penicillin g potassium for injection, usp may be indicated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued. clinical indication infecting organism septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis streptococcus pyogenes (group a β-hemolytic streptococcus), other β-hemolytic streptococci including groups c,h,g,l and m, streptococcus pneumoniae and staphylococcus species (non-penicillinase producing strains) anthrax bacillus anthracis actinomycosis (cervico-facial disease and thoracic and abdominal disease) actinomyces israelii botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) clostridium species diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) corynebacterium diphtheriae erysipelothrix endocarditis erysipelothrix rhusiopathiae fusospirochetosis (severe infections of the oropharynx [vincent’s], lower respiratory tract and genital area) fusobacterium species and spirochetes listeria infections including meningitis and endocarditis listeria monocytogenes pasteurella infections including bacteremia and meningitis pasteurella multocida haverhill fever streptobacillus moniliformis rat bite fever spirillum minus or streptobacillus moniliformis disseminated gonococcal infections neisseria gonorrhoeae (penicillin-susceptible) syphilis (congenital and neurosyphilis) treponema pallidum meningococcal meningitis and / or septicemia neisseria meningitidis gram-negative bacillary infections (bacteremias) penicillin g is not the drug of choice in the treatment of gram-negative bacillary infections . gram -negative bacillary organisms (i.e. enterobacteriaceae)   to reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin g potassium for injection, usp and other antibacterial drugs, penicillin g potassium for injection, usp should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. a history of a hypersensitivity (anaphylactic) reaction to any penicillin is a contraindication.

États-Unis - anglais - NLM (National Library of Medicine)

baxter healthcare corporation - penicillin g potassium (unii: vl775zth4c) (penicillin g - unii:q42t66vg0c) - penicillin g 3000000 [iu] in 50 ml - penicillin g potassium injection, usp is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin g. therapy with penicillin g potassium injection, usp may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued. clinical indication infecting organism septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis streptococcus pyogenes (group a β-hemolytic streptococcus), other β-hemolytic streptococci including groups c, h, g, l and m, streptococcus pneumoniae and staphylococcus species (non-penicillinase producing strains) anthrax bacillus anthrac

États-Unis - anglais - NLM (National Library of Medicine)

sandoz inc - penicillin g potassium (unii: vl775zth4c) (penicillin g - unii:q42t66vg0c) - penicillin g 5000000 [iu] - buffered penicillin g potassium for injection is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin g. therapy with buffered penicillin g potassium for injection may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued. septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis streptococcus pyogenes (group a beta-hemolytic streptococcus ), other beta-hemolytic streptococci including groups c, h, g, l and m, streptococcus pneumoniae and staphylococcus species (non-penicillinase producing strains) anthrax bacillus anthracis actinomycosis (cer

Australie - anglais - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - amoxicillin trihydrate,potassium clavulanate -

Nouvelle-Zélande - anglais - myHealthbox

bayer ag - chlorsulfuron - oil dispersion - thiacloprid 150g/litre; ; deltamethrin 20g/litre  - herbicide - insecticide

Malaisie - anglais - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

healol pharmaceuticals sdn. bhd. - potassium clavulanate; amoxycillin sodium -

États-Unis - anglais - NLM (National Library of Medicine)

boiron - proteus inconstans (unii: utx536wn6n) (proteus inconstans - unii:utx536wn6n), proteus mirabilis (unii: c177vr41dv) (proteus mirabilis - unii:c177vr41dv), proteus morganii (unii: 56x6lid5zy) (proteus morganii - unii:56x6lid5zy), proteus rettgeri (unii: dk2qly70va) (proteus rettgeri - unii:dk2qly70va), proteus vulgaris (unii: 11t9hco30o) (proteus vulgaris - unii:11t9hco30o) - rx only* stop use and ask a doctor if symptoms persist for more than 3 days or worsen

États-Unis - anglais - NLM (National Library of Medicine)

boiron - proteus inconstans (unii: utx536wn6n) (proteus inconstans - unii:utx536wn6n) - rx only* stop use and ask a doctor if symptoms persist for more than 3 days or worsen

États-Unis - anglais - NLM (National Library of Medicine)

physicians total care, inc. - amoxicillin (unii: 804826j2hu) (amoxicillin - unii:804826j2hu), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - amoxicillin 200 mg in 5 ml - amoxicillin and clavulanate potassium for oral suspension and chewable tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: lower respiratory tract infections – caused by β-lactamaseproducing strains of h. influenzae and m. catarrhalis. otitis media – caused by β-lactamase-producing strains of h. influenzae and m. catarrhalis. sinusitis – caused by β-lactamase-producing strains of h. influenzae and m. catarrhalis. skin and skin structure infections – caused by β-lactamaseproducing strains of s. aureus, e. coli and klebsiella spp. urinary tract infections – caused by β-lactamase-producing strains of e. coli, klebsiella spp. and enterobacter spp. while amoxicillin and clavulanate potassium for oral suspension and chewable tablets are indicated only for the conditions listed above, infections caused by ampicillin-susceptible organisms are also amenable to amoxicillin and clavulanate potassium for